NCT02620163View on ClinicalTrials.gov

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

PHASE3CompletedINTERVENTIONAL

Enrollment

381

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Hypertension

Interventions

DRUG

telmisartan/amlodipine 40/5mg

DRUG

YH22162 40/5/12.5 mg

DRUG

telmisartan/amlodipine 80/5mg

DRUG

YH22162 80/5/25 mg

DRUG

telmisartan/amlodipine 40/5mg placebo

DRUG

YH22162 40/5/12.5 mg placebo

DRUG

telmisartan/amlodipine 80/5mg placebo

DRUG

YH22162 80/5/25 mg placebo

Trial Locations (1)

Unknown

Yuhan, Seoul

All Listed Sponsors

lead

Yuhan Corporation

INDUSTRY

NCT02620163 - Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment | Biotech Hunter | Biotech Hunter